Adiponectin, ghrelin, and leptin differentially influence human platelet and human vascular endothelial cell functions: Implication in obesity-associated cardiovascular diseases

European Journal of Pharmacology

Volumn 558, Issue 1-3, 2007, Pages 7-13

  Elbatarny, Hisham S ^a   Netherton, Stuart J ^a   Ovens, Jeffrey D ^a   Ferguson, Alastair V ^a   Maurice, Donald H ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

Adiponectin; Endothelium; Ghrelin; Leptin; Obesity; Platelets

Indexed keywords

ADIPONECTIN; GHRELIN; LEPTIN;

ARTICLE; CARDIOVASCULAR DISEASE; CELL FUNCTION; CELL MEMBRANE PERMEABILITY; CELL TYPE; ENDOTHELIUM CELL; HUMAN; METABOLIC SYNDROME X; MICROVASCULARIZATION; MONOLAYER CULTURE; OBESITY; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE ADHESION; THROMBOCYTE AGGREGATION; THROMBOGENESIS; VASCULAR ENDOTHELIUM;

ADIPONECTIN; CAPILLARY PERMEABILITY; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; HUMANS; LEPTIN; OBESITY; PEPTIDE HORMONES; PLATELET ACTIVATION; PLATELET ADHESIVENESS; PLATELET AGGREGATION;

EID: 33847335031     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2006.11.052     Document Type: Article

References (30)

1. Ahima R.S. Central actions of adipocytes hormones. Trends Endocrinol. Metab. 16 (2005) 307-313
2. Arita Y., Kihara S., Ouchi N., Takahashi M., Maeda K., Miyagawa J., Hotta K., Shimomura I., Nakamura T., Miyaoka K., Kuriyama H., Nishida M., Yamashita S., Okubo K., Matsubara K., Muraguchi M., Ohmoto Y., Funahashi T., and Matsuzawa Y. Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem. Biophys. Res. Commun. 257 (1999) 79-83
3. Baldanzi G., Filigheddu N., Cutrupi S., Catapano F., Bonissoni S., Fubini A., Malan D., Baj G., Granata R., Broglio F., Papotti M., Surico N., Bussolino F., Isgaard J., Deghenghi R., Sinigaglia F., Prat M., Muccioli G., Ghigo E., and Graziani A. Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J. Cell Biol. 159 (2002) 1029-1037
4. Bouloumié A., Drexler H.C.A., Lafontan M., and Busse R. Leptin, the product of Ob gene, promotes angiogenesis. Circ. Res. 83 (1998) 1059-1066
5. Conconi M.T., Nico B., Guidolin D., Baiguera S., Spinazzi R., Rebuffat P., Malendowicz L.K., Vacca A., Carraro G., Parnigotto P.P., Nussdorfer G.G., and Ribatti D. Ghrelin inhibits FGF-2-mediated angiogenesis in vitro and in vivo. Peptides 25 (2004) 2179-2185
6. Detmar M., Velasco P., Richard L., Claffey K.P., Streit M., Riccardi L., Skobe M., and Brown L.F. Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas. Am. J. Pathol. 156 (2000) 159-167
7. Eckel R.H., and Krauss R.M. American heart association call to action: obesity as a major risk factor for coronary heart disease. Circulation 97 (1998) 2099-2100
8. Elbatarny H.S., and Maurice D.H. Leptin-mediated activation of human platelets: involvement of a leptin receptor and phosphodiesterase 3A-containing cellular signaling complex. Am. J. Physiol., Endocrinol Metabol. Gastrointest. Physiol. 289 (2005) E695-E702
9. Emilsson V., Liu Y.L., Cawthorne M.A., Morton N.M., and Devenport M. Expression and functional leptin receptor mRNA in pancreatic islets and direct inhibitory action of leptin on insulin secretion. Diabetes 46 (1997) 313-316
10. Fantuzzi G., and Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J. Leukoc. Biol. 68 (2000) 437-446
11. Haqq A.M., Farooqi I.S., O'Rahilly S., Stadler D.D., Rosenfeld R.G., Pratt K.L., LaFranchi S.H., and Purnell J.Q. Serum ghrelin levels are inversely correlated with body mass index, age, and insulin concentrations in normal children and are markedly increased in Prader-Willi syndrome. J. Clin. Endocrinol. Metab. 88 (2003) 174-178
12. Hug C., and Lodish H.F. The role of the adipocyte hormone adiponectin in cardiovascular disease. Curr. Opin. Pharmacol. 5 (2005) 129-134
13. Kaplan N.M. The deadly quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch. Intern. Med. 149 (1989) 1514-1520
14. Koerner A., Kratzsch J., and Kiess W. Adipocytokines: leptin-the classical, resistin-the controversial, adiponectin-the promising, and more to come. Best Pract. Res. Clin. Endocrinol. Metab. 19 (2005) 525-546
15. Kougias P., Chai H., Lin P.H., Yao Q., Lumsden A.B., and Chen C. Effects of adipocyte-derived cytokines on endothelial functions: implication of vascular disease. J. Surg. Res. 126 (2005) 121-129
16. Lam K.S., and Xu A. Adiponectin: protection of the endothelium. Curr. Diabetes Rep. 5 (2005) 254-259
17. Libè R., Morpurgo P.S., Cappiello V., Maffini A., Bondioni S., Locatelli M., Zavanone M., Beck-Peccoz P., and Spada A. Ghrelin and adiponectin in patients with Cushing's disease before and after successful transsphenoidal surgery. Clin. Endocrinol. 62 (2005) 30-36
18. Maurice D.H., and Haslam R.J. Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: inhibition of cyclic AMP breakdown by cyclic GMP. Mol. Pharmacol. 37 (1990) 671-681
19. Mehta D., and Malik A.B. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 86 (2006) 279-367
20. Nakata M., Tada T., Soejima N., and Maruyama I. Leptin promotes aggregation of human platelets via the long form of its receptor. Diabetes 48 (1999) 426-429
21. Ouchi N., Kihara S., Arita Y., Okamoto Y., Maeda K., Kuriyama H., Hotta K., Nishida M., Takahashi M., Muraguchi M., Ohmoto Y., Nakamura T., Yamashita S., Funahashi T., and Matsuzawa Y. Adiponectin, an adipocytes-derived plasma protein, inhibits endothelial NF-κB signaling through a cAMP-dependent pathway. Circulation 102 (2000) 1296-1301
22. Papotti M., Ghe C., Cassoni P., Catapano F., Deghenghi R., Ghigo E., and Muccioli G. Growth hormone secretagogue binding sites in peripheral human tissues. J. Clin. Endocrinol. Metab. 85 (2000) 3803-3807
23. Piatti P., and Monti L.D. Insulin resistance, hyperleptinemia and endothelial dysfunction in coronary restenosis. Curr. Opin. Pharmacol. 5 (2005) 160-164
24. Sánchez-Margalet V., Martín-Romero C., Santos-Alvarez J., Goberna R., Najib S., and Gonzalez-Yanes C. Role of leptin as an immunomodulator of blood mononuclear cells: mechanisms of action. Clin. Exp. Immunol. 133 (2003) 11-19
25. Sharma V., and McNeill J.H. The emerging roles of leptin and ghrelin in cardiovascular physiology and pathophysiology. Curr. Vasc. Pharmacol. 3 (2005) 169-180
26. Small C.J., and Bloom S.R. Gut hormones and the control of appetite. Trends Endocrinol. Metab. 15 (2004) 259-263
27. Spranger J., Verma S., Gohring I., Bobbert T., Seifert J., Sindler A.L., Pfeiffer A., Hileman S.M., Tschop M., and Banks W.A. Adiponectin does not cross the blood-brain barrier but modifies cytokine expression of brain endothelial cells. Diabetes 55 (2006) 141-147
28. Tesauro M., Schinzari F., Iantorno M., Rizza S., Melina D., Lauro D., and Cardillo C. Ghrelin improves endothelial function in patients with metabolic syndrome. Circulation 112 (2005) 2986-2992
29. Wallace A.M., McMahon A.D., Packard C.J., Kelly A., Shepherd J., Gaw A., and Sattar N. Plasma leptin and the risk of cardiovascular disease in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 104 (2001) 3052-3056
30. Zhao A.Z., Bornfeldt K.E., and Beavo J.A. Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J. Clin. Invest. 102 (1998) 869-873